Compositions and methods for non-genotoxic pretreatment

By combining the Fc effector function with anti-CD110 and anti-CD117 pretreatment agents, endogenous hematopoietic stem cells and transplanting exogenous cells, the genotoxicity problem of the existing methods is solved, safe and effective hematopoietic stem cell transplantation is achieved, the scope of application is expanded and the side effects are reduced.

CN120344562APending Publication Date: 2025-07-18MARO BIO INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202380075661.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-08-29
Filing Date
2023-08-29
Publication Date
2025-07-18

AI Technical Summary

Technical Problem

The existing pretreatment methods for hematopoietic stem cell transplantation are highly genotoxic, resulting in serious side effects, making it difficult to safely and effectively apply in a wide range of patient populations, and the existing targeted CD117 strategy is not sufficient to prepare the subject for successful transplantation.

Method used

Anti-CD110 and anti-CD117 pretreatment agents are used to specifically bind CD110 and CD117, and the Fc effector function is used to mediate the clearance of hematopoietic stem cells, achieving robust depletion of endogenous hematopoietic stem cells, and in conjunction with exogenous hematopoietic stem cell transplantation, avoiding the use of radiation or chemotherapy.

Benefits of technology

It has achieved genotoxicity-free pretreatment, reduced the incidence and mortality related to transplantation, promoted multi-sprite hematopoietic reconstruction, expanded the scope of application of hematopoietic stem cell transplantation, and reduced side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0005376993630000011
    Figure HDA0005376993630000011
  • Figure HDA0005376993630000021
    Figure HDA0005376993630000021
  • Figure HDA0005376993630000031
    Figure HDA0005376993630000031
Patent Text Reader

Abstract

Provided herein are methods and compositions relating to depleting endogenous hematopoietic stem cells in a subject (e.g., prior to hematopoietic stem cell transplantation) using anti-CD110 and anti-CD117 pre-treatment agents. Cell-based therapeutic methods and compositions are also provided.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Anti-c-MPL antibodies

    WO2011060076A1